Financial Performance - Operating revenue for Q1 2024 was CNY 142,234.08, a decline of 44.01% compared to CNY 254,035.40 in Q1 2023[10] - Net loss attributable to shareholders was CNY 85,911,743.21, worsening by 18.33% from a loss of CNY 72,601,501.99 in the same period last year[10] - Total operating revenue for Q1 2024 was 142,234.08, a decrease of 44% compared to 254,035.40 in Q1 2023[46] - Net profit for Q1 2024 was -85,911,743.21, compared to -72,601,501.99 in Q1 2023, indicating a decline in profitability[48] - The total comprehensive income for Q1 2024 was -85,911,743.21, compared to -72,601,501.99 in Q1 2023, showing a worsening financial position[48] Assets and Liabilities - Total assets as of March 31, 2024, reached CNY 1,507,432,459.52, an increase of 3.65% compared to the end of 2023[10] - Total liabilities rose to ¥685,996,593.32, compared to ¥547,373,386.43, indicating an increase of about 25.3%[42] - Current liabilities totaled ¥605,085,521.51, up from ¥500,317,190.06, reflecting a growth of approximately 20.9%[41] - Long-term borrowings increased significantly to ¥62,312,334.13 from ¥29,500,000.00, marking a rise of about 111.5%[41] - The company’s total non-current assets amounted to ¥848,464,052.78, compared to ¥831,206,177.70, reflecting a growth of about 2.0%[44] Shareholder Information - The largest shareholder, Tianlangxing Holdings, holds 22.40% of the shares, totaling 62,944,000 shares[17] - The second largest shareholder, Beijing Jianglinwei Biological Technology, holds 7.90% of the shares, totaling 22,200,000 shares[17] - The total number of unrestricted shares increased from 136,530,680 to 137,634,680, representing a change of 0.8%[16] - The total number of restricted shares decreased from 144,409,320 to 143,305,320, a reduction of approximately 0.76%[16] - The total number of shareholders with unrestricted shares is 5,458[16] Cash Flow and Financing - Cash flow from operating activities showed an improvement, with a net outflow of CNY 44,520,811.78, a 23.90% reduction in outflow compared to CNY 58,503,524.33 in Q1 2023[10] - Operating cash inflow for Q1 2024 reached ¥11,013,421.80, a significant increase from ¥7,756,318.72 in Q1 2023, representing a growth of approximately 42.9%[53] - Net cash outflow from operating activities was ¥44,520,811.78 in Q1 2024, an improvement compared to ¥58,503,524.33 in Q1 2023, indicating a reduction of about 23.8%[53] - Cash inflow from financing activities in Q1 2024 included ¥49,000,000.00 from borrowings, a new source of cash compared to the previous year[58] - The company applied for a comprehensive credit limit of up to 100 million yuan from Beijing Bank, with a maximum approved credit limit of 80 million yuan, guaranteed by major shareholders and executives[29] Expenses and Costs - Total operating costs increased to 86,262,851.85, up from 72,072,542.78, representing an increase of approximately 19.7%[46] - Research and development expenses rose to 62,970,054.89, compared to 53,212,594.76 in the same period last year, marking a 18.4% increase[46] - The company reported a significant increase in tax expenses, with a rise of 66.34% to CNY 386,510.49, mainly due to higher land use and property taxes[12] - Financial expenses for Q1 2024 were 655,719.97, compared to -1,757,532.36 in Q1 2023, indicating a shift from income to expenses[46] - The company experienced a credit impairment loss of -29,128.00, contrasting with a gain of 18,202.98 in the previous year[48] Other Financial Information - Cash and cash equivalents stood at ¥129,630,494.73, down from ¥139,319,843.33, a decrease of approximately 6.0%[43] - The company has no overdue commitments as of the report date[34] - The company has no significant litigation or arbitration matters during the reporting period[26] - The company has implemented an employee incentive plan, which has been approved by the shareholders' meeting[24] - The company is actively promoting the issuance of H shares on the Hong Kong Stock Exchange, pending approval from regulatory authorities[36]
康乐卫士(833575) - 2024 Q1 - 季度财报